Premier Invests In Exela To Procure Shortage-Hit Generic Injectables
Participating Premier Health Systems Sign Multi-Year Purchasing Commitments
As hospital drug shortages continue to bite in the US, a group purchasing organization has invested in generic injectables specialist Exela Pharma Sciences to garner uninterrupted supply of 19 pharmaceutical products.
You may also be interested in...
High-level board will bring together information from across FDA drug center and work to increase supply chain transparency, CDER’s Jacqueline Corrigan-Curay, who will chair the group, tells the Pink Sheet.
After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.
Phlow Corp has announced a strategic alliance with the US Pharmacopeia to certify and validate continuous manufacturing processes as it aims to bolster US supplies of essential medicines. The company believes the move could serve as a catalyst for wider generics industry adoption of continuous manufacturing.